Home » Stocks » TXMD

TherapeuticsMD, Inc. (TXMD)

Stock Price: $1.38 USD -0.06 (-4.17%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.37 -0.01 (-0.73%) Jan 15, 7:59 PM
Market Cap 413.68M
Revenue (ttm) 58.20M
Net Income (ttm) -190.87M
Shares Out 272.56M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.38
Previous Close $1.44
Change ($) -0.06
Change (%) -4.17%
Day's Open 1.43
Day's Range 1.38 - 1.46
Day's Volume 5,286,629
52-Week Range 0.87 - 2.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 5 days ago

TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Business Wire - 2 weeks ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at H.C. Wainwright BioConnect Conference and J.P. Morgan Virtual HealthCare Conference in January 2021

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD closes offering; sold 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock f...

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day opti...

Seeking Alpha - 2 months ago

TherapeuticsMD's (TXMD) CEO Robert Finizio on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 2.5% in pre-market trading after the company reported Q3 results.

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD releases Q3 business and financial results; holds conference call at 8:30 am ET today

Zacks Investment Research - 2 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to hold conference call to discuss Q3 financial and business results on Monday, November 9 at 8:30 am ET

Zacks Investment Research - 2 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 2 months ago

Give TXMD stock a try if you're ready to expand your portfolio's horizons with a stake in innovative women's health care products. The post Delve into an Underappreciated Health Care Niche wit...

Business Wire - 3 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choic...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

Business Wire - 3 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--3Q Update PR

GlobeNewsWire - 3 months ago

MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today th...

Other stocks mentioned: KHTRF
Business Wire - 4 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD to participate in two virtual investor conferences in September

Business Wire - 4 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD increases patent protection on ANNOVERA

Seeking Alpha - 4 months ago

TherapeuticsMD has been a blemish on my speculative biotech/pharma portfolio for over a year. I went against my rules for trading a premium-priced bio and paid for it.

GlobeNewsWire - 4 months ago

MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the ...

Seeking Alpha - 5 months ago

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD discusses business and financial results for Q2 2020 on earnings conference call today at 8:30 a.m.

Zacks Investment Research - 5 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc.

Zacks Investment Research - 5 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

BOCA RATON, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--TXMD expands access to Annovera through arrangement with Nurx, the largest online practice for women's health

Forbes - 6 months ago

Being concerned about the elevated levels of the market is likely to be on many investors’ minds ahead of a slew of corporate earnings coming, not to mention an election season that is only go...

Other stocks mentioned: AIRG, BHF, SLNO, VECO
The Motley Fool - 7 months ago

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.

Other stocks mentioned: ENDP, MYL
Seeking Alpha - 8 months ago

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 8 months ago

A newly issued patent could provide market exclusivity for its long-term contraceptive device.

Zacks Investment Research - 8 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

Seeking Alpha - 10 months ago

TherapeuticsMD Reports Encouraging Q4/2019 Earnings But The Market Doesn't Care

Seeking Alpha - 10 months ago

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.00% and 20.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 11 months ago

The company already has three women's healthcare products available on the market.

Seeking Alpha - 11 months ago

TherapeuticsMD: Inside The Numbers

The Motley Fool - 11 months ago

Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.

Seeking Alpha - 1 year ago

TherapeuticsMD's Business Model Affirms Additional Dilution Is Practically Certain In FY2020

Seeking Alpha - 1 year ago

TherapeuticsMD: Hits Upper-End Of Q3 Guidance And Establishes Momentum Into 2020

Seeking Alpha - 1 year ago

TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Investors are bracing for dilution from a proposed share offering.

The Motley Fool - 1 year ago

The path ahead is looking a bit brighter for this pharmaceutical company.

The Motley Fool - 1 year ago

August sales figures suggest the company's strategy is working.

About TXMD

TherapeuticsMD operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Robert Finizio
Employees
348
Stock Exchange
NASDAQ
Ticker Symbol
TXMD
Full Company Profile

Financial Performance

In 2019, TherapeuticsMD's revenue was $49.65 million, an increase of 208.38% compared to the previous year's $16.10 million. Losses were -$176.14 million, 32.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TherapeuticsMD stock is "Strong Buy." The 12-month stock price forecast is 6.43, which is an increase of 365.94% from the latest price.

Price Target
$6.43
(365.94% upside)
Analyst Consensus: Strong Buy